Cargando…

PB2027: EFFICACY OF THERAPY IN PATIENTS WITH NEWLY DIAGNOSED MYELODYSPLASTIC SYNDROME WITH UNFAVORABLE IMMUNOPHENOTYPIC AND CYTOGENETIC PROGNOSIS.

Detalles Bibliográficos
Autores principales:	Trubkina, Hanna, Iskrou, Ihar, Lendzina, Iryna, Lebedeva, Tatiana, Smolnikova, Viktirya
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams & Wilkins 2023
Materias:	Publication Only
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10430242/ http://dx.doi.org/10.1097/01.HS9.0000974916.51447.bd

Ejemplares similares

PB1996: CYTOGENETIC FEATURES OF 164 MOROCCAN PATIENTS WITH MYELODYSPLASTIC SYNDROME
por: Aghoutane, Yossra, et al.
Publicado: (2023)

PB1914: CYTOGENETIC FINDINGS IN 18 CHILDREN WITH MYELODYSPLASTIC SYNDROMES BY KARYOTYPIC AND FISH ANALYSIS
por: Manola, K., et al.
Publicado: (2022)

PB2027: PROGNOSTICATION IN THE EVERYDAY MYELOMA CLINIC. A SYSTEMATIC REVIEW OF PROGNOSTIC MODELS VALIDATED IN REAL WORLD POPULATIONS
por: Redder, L., et al.
Publicado: (2022)

PB2256: BACTERIAL BLOODSTREAM INFECTIONS AND ANTIMICROBIAL SUSCEPTIBILITY PATTERN IN PATIENTS WITH ACUTE LEUCAEMIA
por: Balshova, N., et al.
Publicado: (2022)

PB1753: EVALUATION OF IMMUNOPHENOTYPIC CHARACTERISTICS OF RESIDUAL CELLS IN COMPARISON WITH NORMAL HEMATOGONES AND MATURE CELLS IN CHILDREN WITH B-CELL LYMPHOBLASTIC LEUKEMIA
por: Karnabeda, Oksana, et al.
Publicado: (2023)

PB2023: UPDATE AND FOLLOW-UP OF NEWLY DIAGNOSED MULTIPLE MYELOMA (NDMM) WITH HIGH-RISK CYTOGENETIC (HRC).
por: Nuevo López, M. I., et al.
Publicado: (2022)

PB2081: CYTOGENETICS OF MULTIPLE MYELOMA IN MOROCCO
por: Moutmir, Yasmine, et al.
Publicado: (2023)

PB1994: COMPARISON OF PATIENTS WITH MYELODYSPLASTIC SYNDROMES WITH HIGH AND LOW OGATA SCORE VALUES ON CYTOMETRY IN RELATION TO THE PRESENCE OF CYTOGENETIC ABNORMALITIES - A PRELIMINARY STUDY
por: Gawronski, Krzysztof, et al.
Publicado: (2023)

PB1997: TRISOMY 18 IN MYELODYSPLASTIC SYNDROMES
por: Abdelmoula, Nouha Bouayed, et al.
Publicado: (2023)

PB2599: THE FREQUENCY OF PHENOTYPES OF THE MNS, KIDD, DUFFY SYSTEMS IN PATIENTS OF THE HEMATOLOGY CLINIC
por: Yovdiy, Anna, et al.
Publicado: (2023)

PB1730: PROGNOSTIC VALUE OF EARLY T-ALL IMMUNOPHENOTYPES IN ADULTS ON THE RALL-2016 PROTOCOL
por: Vasileva, Anastasia, et al.
Publicado: (2023)

PB2015: DIAGNOSIS, CLASSIFICATION AND STRATIFICATION OF MYELODYSPLASTIC SYNDROMES IN ALGERIA
por: Moussa, Yamina Bouchakour, et al.
Publicado: (2023)

PB2020: OUTCOMES OF PATIENTS WITH HIGH RISK MYELODYSPLASTIC SYNDROMES
por: Amor, Imen Ben, et al.
Publicado: (2023)

PB2025: CULTURAL DATA TO NEW CLASSIFICATION OF MYELODYSPLASTIC NEOPLASIA
por: Saralidze, Tamar, et al.
Publicado: (2023)

PB2010: FIRST-LINE TREATMENT PATTERNS AND OUTCOMES AMONG PATIENTS WITH NEWLY DIAGNOSED MYELODYSPLASTIC SYNDROMES: A GLOBAL, RETROSPECTIVE OBSERVATIONAL COHORT STUDY
por: Zeidan, Amer M., et al.
Publicado: (2023)

PB1916: SOMATIC MUTATIONS ASSOCIATED WITH MYELODYSPLASTIC SYNDROME IN RUSSIAN PATIENTS
por: Kohno, A., et al.
Publicado: (2022)

PB1992: PROTEOMIC ANALYSIS REVEALS AUTOPHAGY INHIBITION IN MYELODYSPLASTIC SYNDROMES
por: Tsekoura, Georgia, et al.
Publicado: (2023)

PB1784: CYTOGENETIC LANDSCAPE OF 87 MOROCCAN ACUTE MYELOID LEUKEMIA PATIENTS
por: Mahtat, E. M., et al.
Publicado: (2022)

PB2477: INTEGRATION OF OPTICAL GENOME MAPPING IN DAILY CYTOGENETICS LABORATORY ROUTINE.
por: Díaz González, Álvaro, et al.
Publicado: (2023)

PB2026: ROLE OF MOLECULAR PROFILING IN MYELODYSPLASTIC SYNDROME IN REAL-WORLD - A NEW APPROACH IN MYELODYSPLASTIC SYNDROME’S RISK STRATIFICATION?
por: Silva, Duarte Pacheco, et al.
Publicado: (2023)

PB2038: LENALIDOMIDE OR BORTEZOMIB AS MAINTENANCE TREATMENT OVERCOMES INFERIOR IMPACT OF HIGH-RISK CYTOGENETIC ABNORMALITIES IN TRANSPLANT-INELIGIBLE PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA IN CHINA
por: Zhuang, Z., et al.
Publicado: (2022)

PB2029: ACQUIRED ALPHA THALASSEMIA IN ASSOCIATION WITH MYELODYSPLASTIC SYNDROME- A CASE REPORT
por: Balasubramanian, Priyavadhana, et al.
Publicado: (2023)

PB2011: TRANSFUSION BURDEN IS AN IMPORTANT PROGNOSTIC FACTOR IN LOWER-RISK MYELODYSPLASTIC SYNDROME
por: Lee, Jungmin, et al.
Publicado: (2023)

PB2013: THE FREQUENCY, EVOLUTION AND SIGNIFICANCE OF GENE MUTATION IN MYELODYSPLASTIC SYNDROMES WITH NORMAL KARYOTYPE
por: Xu, Feng, et al.
Publicado: (2023)

PB1920: CLINICOHEMATOLIGICAL CHARACTERISTICS AND CYTOGENETIC PROFILE OF CHRONIC MYELOMONOCYTIC LEUKEMIA; AN EXPERIENCE FROM PAKISTAN
por: ANWAR, N., et al.
Publicado: (2022)

PB1845: A MULTIOMIC, SINGLE-CELL MEASURABLE RESIDUAL DISEASE (SCMRD) ASSAY FOR PHASING DNA MUTATIONS AND SURFACE IMMUNOPHENOTYPES
por: Murphy, Charlie, et al.
Publicado: (2023)

PB2022: ELTROMBOPAG IN MYELODYSPLASTIC SYNDROME AND CHRONIC MYELOMONOCYTIC LEUKEMIA: A SINGLE-CENTER EXPERIENCE
por: Peña, Amaia Lopez, et al.
Publicado: (2023)

PB2001: PROGNOSTIC FACTORS IN MYELODYSPLASTIC SYNDROMES- A SWEDISH RETROSPECTIVE REAL-WORLD STUDY
por: Schain, Frida, et al.
Publicado: (2023)

PB2495: QUANTIFICATION AND IMMUNOPHENOTYPIC CHARACTERISATION OF CAR T-CELLS BY FLOW CYTOMETRY AND CORRELATION WITH CLINICAL OUTCOMES FOR PATIENTS WITH LARGE B CELL LYMPHOMA
por: Wayte, Rebecca, et al.
Publicado: (2023)

PB1846: ALTERATIONS IN PRIMARY HEMOSTASIS AS ADDITIONAL RISK FACTORS OF BLEEDING IN PATIENTS WITH NEWLY DIAGNOSED ACUTE MYELOID LEUKEMIA (AML): UPDATED PROSPECTIVE ANALYSIS.
por: Stupakova, Z., et al.
Publicado: (2022)

PB2263: SUPPORTIVE CARE IN LOW-RISK MYELODYSPLASTIC SYNDROMES: ROLE OF ERYTHROPOIESIS STIMULATING AGENTS (ESAS)
por: Cerchione, C., et al.
Publicado: (2022)

PB1923: PATIENT AND PHYSICIAN CHARACTERISTICS ASSOCIATED WITH HYPOMETHYLATING AGENT USE IN HIGHER-RISK MYELODYSPLASTIC SYNDROMES
por: Zeidan, A., et al.
Publicado: (2022)

PB2672: EXPLORING UNMET NEEDS OF PATIENTS WITH MYELODYSPLASTIC NEOPLASMS AND CAREGIVERS IN A NATIONAL ITALIAN SURVEY
por: Crisà, Elena, et al.
Publicado: (2023)

PB2012: DESCRIBING TREATMENT PATTERNS IN PATIENTS WITH MYELODYSPLASTIC SYNDROME ACCORDING TO IPSS-R RISK CATEGORY
por: Corry, Sorcha, et al.
Publicado: (2023)

PB1839: CYTOGENETIC PROFILE OF ACUTE MYELOBLASTIC LEUKEMIA TREATED AT THE MOHAMMED V MILITARY HOSPITAL IN RABAT (MOROCCO).
por: Hawa, Moussa Bouh, et al.
Publicado: (2023)

PB2283: IN THE ERA OF IMMUNOPHENOTYPING AND MOLECULAR DIAGNOSTICS DOES MORPHOLOGY PLAY AN ESSENTIAL ROLE IN DIFFERENTIATING HAIRY CELL LEUKEMIA FROM ITS MIMICS?
por: Balasubramanian, Priyavadhana, et al.
Publicado: (2023)

PB1924: ARE WE TAKING ADVANTAGE OF THERAPEUTIC OPTIONS IN MYELODYSPLASTIC SYNDROME?-REAL WORLD DATA FROM HUNGARY
por: Miltényi, Z., et al.
Publicado: (2022)

PB2206: FULL SPECTRAL FLOW CYTOMETRY ANALYSIS OF THE BONE MARROW IMMUNE MICROENVIRONMENT IN PATIENTS WITH MYELODYSPLASTIC SYNDROME
por: chen, M., et al.
Publicado: (2022)

PB1917: PROGNOSTIC AND PREDICTIVE SIGNIFICANCE OF ELEMENTS OF THE ADAPTIVE IMMUNITY IN THE MICROENVIRONMENT OF MYELODYSPLASTIC SYNDROMES TREATED WITH 5-AZACITIDINE
por: Tsakiraki, Z., et al.
Publicado: (2022)

PB2007: INTEGRATION OF TELEHEALTH IN DAILY CLINICAL PRACTICE IN PATIENTS WITH MYELODYSPLASTIC NEOPLASMS - STATUS QUO AND FUTURE PERSPECTIVES
por: Stauder, Reinhard, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_s2ukbqrcm8g7did24h8mctn8tv